These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29970892)

  • 1. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer.
    Wang Q; Shi YL; Zhou K; Wang LL; Yan ZX; Liu YL; Xu LL; Zhao SW; Chu HL; Shi TT; Ma QH; Bi J
    Cell Death Dis; 2018 Jul; 9(7):739. PubMed ID: 29970892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer.
    Abdalla AN; Malki WH; Qattan A; Shahid I; Hossain MA; Ahmed M
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33440689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
    Chen Z; Wang C; Dong H; Wang X; Gao F; Zhang S; Zhang X
    Mol Med; 2020 Jan; 26(1):14. PubMed ID: 32000660
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOA5 alleviates reactive oxygen species to promote oxaliplatin resistance in PIK3CA-mutated colorectal cancer.
    Liu YL; Xiang Z; Zhang BY; Zou YW; Chen GL; Yin L; Shi YL; Xu LL; Bi J; Wang Q
    Aging (Albany NY); 2024 Jun; 16(11):9410-9436. PubMed ID: 38848145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
    Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer.
    Hsu HC; Liu YS; Tseng KC; Hsu CL; Liang Y; Yang TS; Chen JS; Tang RP; Chen SJ; Chen HC
    Int J Colorectal Dis; 2013 Nov; 28(11):1535-46. PubMed ID: 23784051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
    Khan N; Jajeh F; Eberhardt EL; Miller DD; Albrecht DM; Van Doorn R; Hruby MD; Maresh ME; Clipson L; Mukhtar H; Halberg RB
    Int J Cancer; 2019 Dec; 145(11):3022-3032. PubMed ID: 31018249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.
    Zhu YF; Yu BH; Li DL; Ke HL; Guo XZ; Xiao XY
    World J Gastroenterol; 2012 Jul; 18(28):3745-51. PubMed ID: 22851869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
    Domingo E; Church DN; Sieber O; Ramamoorthy R; Yanagisawa Y; Johnstone E; Davidson B; Kerr DJ; Tomlinson IP; Midgley R
    J Clin Oncol; 2013 Dec; 31(34):4297-305. PubMed ID: 24062397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.
    Mei ZB; Duan CY; Li CB; Cui L; Ogino S
    Ann Oncol; 2016 Oct; 27(10):1836-48. PubMed ID: 27436848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
    Fernandes MS; Melo S; Velho S; Carneiro P; Carneiro F; Seruca R
    Oncotarget; 2016 Oct; 7(42):68546-68558. PubMed ID: 27602501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
    Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway.
    Chen W; Dai G; Qian Y; Wen L; He X; Liu H; Gao Y; Tang X; Dong B
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
    Hao Y; Samuels Y; Li Q; Krokowski D; Guan BJ; Wang C; Jin Z; Dong B; Cao B; Feng X; Xiang M; Xu C; Fink S; Meropol NJ; Xu Y; Conlon RA; Markowitz S; Kinzler KW; Velculescu VE; Brunengraber H; Willis JE; LaFramboise T; Hatzoglou M; Zhang GF; Vogelstein B; Wang Z
    Nat Commun; 2016 Jun; 7():11971. PubMed ID: 27321283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.